These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 32066201)

  • 1. Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma.
    Wong KY; Chim CS
    J Pharm Pharmacol; 2020 May; 72(5):728-737. PubMed ID: 32066201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.
    Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N
    Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal
    Prukova D; Andera L; Nahacka Z; Karolova J; Svaton M; Klanova M; Havranek O; Soukup J; Svobodova K; Zemanova Z; Tuskova D; Pokorna E; Helman K; Forsterova K; Pacheco-Blanco M; Vockova P; Berkova A; Fronkova E; Trneny M; Klener P
    Clin Cancer Res; 2019 Jul; 25(14):4455-4465. PubMed ID: 31004002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma.
    Algarín EM; Quwaider D; Campos-Laborie FJ; Díaz-Tejedor A; Mogollón P; Vuelta E; Martín-Sánchez M; San-Segundo L; González-Méndez L; Gutiérrez NC; García-Sanz R; Paíno T; De Las Rivas J; Ocio EM; Garayoa M
    Cells; 2021 Mar; 10(3):. PubMed ID: 33806619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
    Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
    Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes.
    Seiller C; Maiga S; Touzeau C; Bellanger C; Kervoëlen C; Descamps G; Maillet L; Moreau P; Pellat-Deceunynck C; Gomez-Bougie P; Amiot M
    Cell Death Dis; 2020 May; 11(5):316. PubMed ID: 32371863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma.
    Algarín EM; Díaz-Tejedor A; Mogollón P; Hernández-García S; Corchete LA; San-Segundo L; Martín-Sánchez M; González-Méndez L; Schoumacher M; Banquet S; Kraus-Berthier L; Kloos I; Derreal A; Halilovic E; Maacke H; Gutiérrez NC; Mateos MV; Paíno T; Garayoa M; Ocio EM
    Haematologica; 2020 Mar; 105(3):e116-e120. PubMed ID: 31320555
    [No Abstract]   [Full Text] [Related]  

  • 8. Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence.
    Kitadate A; Terao T; Narita K; Ikeda S; Takahashi Y; Tsushima T; Miura D; Takeuchi M; Takahashi N; Matsue K
    Cancer Sci; 2021 Sep; 112(9):3645-3654. PubMed ID: 34288263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).
    Bahlis NJ; Baz R; Harrison SJ; Quach H; Ho SJ; Vangsted AJ; Plesner T; Moreau P; Gibbs SD; Coppola S; Yang X; Al Masud A; Ross JA; Bueno O; Kaufman JL
    J Clin Oncol; 2021 Nov; 39(32):3602-3612. PubMed ID: 34388020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.
    Ramsey HE; Fischer MA; Lee T; Gorska AE; Arrate MP; Fuller L; Boyd KL; Strickland SA; Sensintaffar J; Hogdal LJ; Ayers GD; Olejniczak ET; Fesik SW; Savona MR
    Cancer Discov; 2018 Dec; 8(12):1566-1581. PubMed ID: 30185627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
    Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
    Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression.
    Gupta VA; Barwick BG; Matulis SM; Shirasaki R; Jaye DL; Keats JJ; Oberlton B; Joseph NS; Hofmeister CC; Heffner LT; Dhodapkar MV; Nooka AK; Lonial S; Mitsiades CS; Kaufman JL; Boise LH
    Blood; 2021 Jul; 137(26):3604-3615. PubMed ID: 33649772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.
    Moreau P; Chanan-Khan A; Roberts AW; Agarwal AB; Facon T; Kumar S; Touzeau C; Punnoose EA; Cordero J; Munasinghe W; Jia J; Salem AH; Freise KJ; Leverson JD; Enschede SH; Ross JA; Maciag PC; Verdugo M; Harrison SJ
    Blood; 2017 Nov; 130(22):2392-2400. PubMed ID: 28847998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance.
    Liu F; Zhao Q; Su Y; Lv J; Gai Y; Liu S; Lin H; Wang Y; Wang G
    Exp Hematol; 2022 Jan; 105():39-49. PubMed ID: 34767916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCL2 blockade overcomes MCL1 resistance in multiple myeloma.
    Siu KT; Huang C; Panaroni C; Mukaihara K; Fulzele K; Soucy R; Thorburn C; Cidado J; Drew L; Chattopadhyay S; Raje N
    Leukemia; 2019 Aug; 33(8):2098-2102. PubMed ID: 30816329
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeting Bcl-2 for the treatment of multiple myeloma.
    Touzeau C; Maciag P; Amiot M; Moreau P
    Leukemia; 2018 Sep; 32(9):1899-1907. PubMed ID: 30076373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural history of multiple myeloma patients refractory to venetoclax: A single center experience.
    Maples KT; Nooka AK; Gupta V; Joseph NS; Heffner LT; Hofmeister C; Dhodapkar M; Matulis SM; Lonial S; Boise LH; Kaufman JL
    Am J Hematol; 2021 Mar; 96(3):E68-E71. PubMed ID: 33275813
    [No Abstract]   [Full Text] [Related]  

  • 18. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies.
    Ten Hacken E; Valentin R; Regis FFD; Sun J; Yin S; Werner L; Deng J; Gruber M; Wong J; Zheng M; Gill AL; Seiler M; Smith P; Thomas M; Buonamici S; Ghia EM; Kim E; Rassenti LZ; Burger JA; Kipps TJ; Meyerson ML; Bachireddy P; Wang L; Reed R; Neuberg D; Carrasco RD; Brooks AN; Letai A; Davids MS; Wu CJ
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells.
    Li Z; He S; Look AT
    Leukemia; 2019 Jan; 33(1):262-266. PubMed ID: 30008477
    [No Abstract]   [Full Text] [Related]  

  • 20. Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients-a single-center retrospective study.
    Regidor B; Goldwater MS; Wang J; Bujarski S; Swift R; Eades B; Emamy-Sadr M; Eshagian S; Schwartz G; Spektor TM; Berenson JR
    Ann Hematol; 2021 Aug; 100(8):2061-2070. PubMed ID: 33987683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.